Functional analysis reveals that RBM10 mutations contribute to lung adenocarcinoma pathogenesis by deregulating splicing
RBM10 is an RNA splicing regulator that is frequently mutated in lung adenocarcinoma (LUAD) and has recently been proposed to be a cancer gene. How RBM10 mutations observed in LUAD affect its normal functions, however, remains largely unknown. Here integrative analysis of RBM10 mutation and RNA expr...
Gespeichert in:
Veröffentlicht in: | Scientific reports 2017-01, Vol.7 (1), p.40488-40488, Article 40488 |
---|---|
Hauptverfasser: | , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | RBM10
is an RNA splicing regulator that is frequently mutated in lung adenocarcinoma (LUAD) and has recently been proposed to be a cancer gene. How
RBM10
mutations observed in LUAD affect its normal functions, however, remains largely unknown. Here integrative analysis of
RBM10
mutation and RNA expression data revealed that LUAD-associated
RBM10
mutations exhibit a mutational spectrum similar to that of tumor suppressor genes. In addition, this analysis showed that
RBM10
mutations identified in LUAD patients lacking canonical oncogenes are associated with significantly reduced
RBM10
expression. To systematically investigate
RBM10
mutations, we developed an experimental pipeline for elucidating their functional effects. Among six representative LUAD-associated
RBM10
mutations, one nonsense and one frameshift mutation caused loss-of-function as expected, whereas four missense mutations differentially affected
RBM10
-mediated splicing. Importantly, changes in proliferation rates of LUAD-derived cells caused by these
RBM10
missense mutants correlated with alterations in RNA splicing of
RBM10
target genes. Together, our data implies that
RBM10
mutations contribute to LUAD pathogenesis, at least in large part, by deregulating splicing. The methods described in this study should be useful for analyzing mutations in additional cancer-associated RNA splicing regulators. |
---|---|
ISSN: | 2045-2322 2045-2322 |
DOI: | 10.1038/srep40488 |